Diapharma Announces Partnership with Zacros

Posted: August 7, 2020

T-TAS thrombus formation analysis

August 7, 2020 – Diapharma Group is pleased to announce that it has entered into an exclusive partnership with ZACROS.

Fujimori Kogyo Co., Ltd (ZACROS), headquartered in Tokyo, Japan, and Diapharma Group (Diapharma), headquartered in West Chester, Ohio, have entered into an exclusive agreement for the distribution of the T-TAS®01 (Total Thrombus-formation Analysis System) products in the United States and Canada.

The T-TAS 01 system is the world’s first instrument for the quantification of thrombus forming ability of the blood under physiological flow conditions. The T-TAS 01 with PL chip has been cleared by the US Food and Drug Administration (FDA) for the analysis and evaluation of platelet thrombus formation in patients receiving antiplatelet therapy—including aspirin, clopidogrel, prasugrel and ticagrelor—and in patients with primary hemostasis abnormalities such as Glanzmann’s thrombasthenia or von Willebrand’s Disease.

Diapharma is a distributor of hemostasis and coagulation products in the US and Canada. Diapharma delivers an established customer base performing diagnostic as well as basic and clinical research in thrombosis, hemostasis, bleeding, and clotting disorders. Diapharma has expertise with instrument sales for the hemostasis market and expects to support the launch of the T-TAS 01 instrument and consumables for sales to clinical laboratories performing testing related to coagulation and bleeding.

Diapharma offers a robust technical support staff and technically savvy outside salesforce that can educate users about the features of the T-TAS 01 products.

Together, Diapharma and ZACROS plan to provide solutions to researchers and clinicians in the fields of thrombosis and hemostasis.